Atea Pharmaceuticals Q2 2024 GAAP EPS $(0.48) Beats $(0.77) Estimate
Portfolio Pulse from Benzinga Newsdesk
Atea Pharmaceuticals (NASDAQ:AVIR) reported a Q2 2024 GAAP EPS of $(0.48), beating the analyst consensus estimate of $(0.77) by 37.66%.
August 07, 2024 | 9:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atea Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.48), which is significantly better than the analyst consensus estimate of $(0.77). This positive earnings surprise may boost investor confidence in the short term.
The better-than-expected earnings report indicates that Atea Pharmaceuticals is performing better than analysts anticipated, which is likely to positively impact the stock price in the short term as investors react to the positive news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100